Related Experiment Video
Updated: Jun 10, 2026
09:42
A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model
Published on: June 4, 2021
[Thrombotic-thrombocytopenic purpura]
M Hellmann1, M Hallek, I Scharrer
1Klinik I für Innere Medizin, Universitätsklinikum Köln, Kerpener Straße 62, 50937 Köln, Deutschland. matthias.hellmann@uk-koeln.de
Der Internist
|August 7, 2010
Summary
Thrombotic-thrombocytopenic purpura (TTP) is a serious blood disorder caused by a deficiency in the ADAMTS13 enzyme. Rituximab offers potential as an effective therapy for TTP, reducing the need for plasma exchange.
Area of Science:
- Hematology
- Immunology
- Pathophysiology
Background:
- Thrombotic-thrombocytopenic purpura (TTP) is a critical microangiopathic disorder.
- It involves microthrombi formation due to ultra-large von Willebrand Factor (vWF) multimers.
- This is caused by deficient activity of the vWF-cleaving enzyme, ADAMTS13.
Purpose of the Study:
- To investigate the role of ADAMTS13 deficiency in TTP pathogenesis.
- To evaluate the efficacy of rituximab in TTP treatment.
- To understand the clinical presentation and management of TTP.
Main Methods:
- Review of TTP pathophysiology and enzyme deficiency.
- Analysis of clinical presentation including schistocytes, hemolysis, thrombocytopenia, and neurological symptoms.
- Assessment of therapeutic strategies, including plasmapheresis and rituximab.
Main Results:
- ADAMTS13 deficiency, due to genetic mutation or autoantibodies, underlies TTP.
- Early plasmapheresis is crucial for likely primary TTP.
- Rituximab targets ADAMTS13 autoantibody production, potentially shortening plasma exchange duration.
Conclusions:
- TTP is a life-threatening condition requiring prompt hematological care.
- Rituximab shows promise for TTP management, particularly in relapsed cases or as initial therapy.
- Understanding ADAMTS13's role is key to TTP treatment advancements.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:30Venous Thrombosis I: Introduction
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
01:19Pulmonary Embolism I: Introduction
A blood clot, or thrombus, is a semi-solid mass composed of fibrin, platelets, and red blood cells. When it forms within a vessel, it can obstruct blood flow, known as thrombosis. If part of the clot detaches, it becomes an embolus that can travel and block distant vessels. When this occurs in the pulmonary arteries, it causes a condition known as pulmonary embolism (PE).Origin and ImpactMost often, the embolus originates from a thrombus in the deep veins of the lower limbs, a condition called...
01:29Pulmonary Embolism I: Introduction
Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
01:26Transient Ischemic Attack l: Introduction
A transient ischemic attack (TIA) is a brief episode of neurological dysfunction caused by a temporary, focal reduction in cerebral blood flow. Although symptoms resemble those of an ischemic stroke, the interruption in perfusion is short-lived and does not cause permanent infarction. TIAs are clinically important because they often serve as early warning events for future stroke.Mechanisms of Transient Cerebral IschemiaTransient cerebral ischemia may arise through several mechanisms. One...
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...